Last reviewed · How we verify
NCT03770858
Wearable Skin Sensors to Assess Nocturnal Scratch Behavior
trial testing Crisaborole in Atopic Dermatitis in 23 participants. Completed in 24 August 2022.
30 August 2021
Quick facts
| Lead sponsor | Northwestern University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 23 |
| Start date | 18 April 2019 |
| Primary completion | 30 August 2021 |
| Estimated completion | 24 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Crisaborole (Crisaborole) — full drug profile →
- Scratch sensor
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Northwestern University
Who can join
2 and older, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pilot study of flexible and wearable sensor to monitor nocturnal scratching behavior
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Implication of Phosphodiesterase-4-Inhibition.
Schick MA, Schlegel N. · · 2022 · cited 56× · PMID 35163131 · DOI 10.3390/ijms23031209
Verify or expand the search:
- PubMed search for NCT03770858
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Crisaborole
Trials testing the same drug.
- NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
- NCT03832010 — Steroid-reducing Effects of Crisaborole · Phase 4 · completed
- NCT04023084 — Response of Children With Atopic Dermatitis (Eczema) to Eucrisa · Phase 4 · completed
- NCT03645057 — ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis · Phase 3 · completed
- NCT03567980 — A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrhei · Phase 4 · completed
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Northwestern University trials
Trials by the same sponsor.
- NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
- NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
- NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
- NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
- NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03770858 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Northwestern University
- Last refreshed: 13 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03770858.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing